In addition, point mutations and small insertions/deletions (INDELs) have also been described leading to oncogenic events, such as mutations activatingNOTCH1that occur in more than 60% of T-ALL cases[10], or mutations in cytokine receptors and tyrosine kinases such asIL7RandJAK3[11][17]

In addition, point mutations and small insertions/deletions (INDELs) have also been described leading to oncogenic events, such as mutations activatingNOTCH1that occur in more than 60% of T-ALL cases[10], or mutations in cytokine receptors and tyrosine kinases such asIL7RandJAK3[11][17]. classify patients into T-ALL subtypes. Finally, we detected gene fusions, of which several can explain the over-expression of key driver genes such asTLX1, PLAG1, LMO1, orNKX2-1; and others result in novel fusion transcripts encoding activated kinases (SSBP2-FERandTPM3-JAK2) or involvingMLLT10. In conclusion, we present novel analysis pipelines for variant calling, variant filtering, and expression normalization on RNA-seq data, and successfully applied these for the detection of translocations, point mutations, INDELs, exon-skipping events, and expression perturbations in T-ALL. == Author Summary == The quest for somatic mutations underlying oncogenic processes is a Tetrahydrozoline Hydrochloride central theme in today’s cancer research. High-throughput genomics approaches including amplicon re-sequencing, exome re-sequencing, full genome re-sequencing, and SNP arrays have contributed to cataloguing driver genes across cancer types. Thus far transcriptome sequencing by RNA-seq has been mainly used for the detection of fusion genes, while few studies have assessed its value for the combined detection of SNPs, INDELs, fusions, gene expression changes, and alternative transcript Rabbit polyclonal to HDAC5.HDAC9 a transcriptional regulator of the histone deacetylase family, subfamily 2.Deacetylates lysine residues on the N-terminal part of the core histones H2A, H2B, H3 AND H4. events. Here we apply RNA-seq to 49 T-ALL samples and perform a critical assessment of the bioinformatics pipelines and filters to identify each type of aberration. By comparing to exome re-sequencing, and by exploiting the catalogues of known cancer drivers, we identified many known and several novel driver genes in T-ALL. We also determined an optimal normalization strategy to Tetrahydrozoline Hydrochloride obtain accurate gene expression levels and used these to identify over-expressed transcription factors that characterize different T-ALL subtypes. Finally, by PCR, cloning, andin vitrocellular assays we uncover new fusion genes that have consequences at the level of gene expression, oncogenic chimaeras, and tumor suppressor inactivation. In conclusion, we present the first RNA-seq data set across T-ALL patients and identify new driver events. == Introduction == T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that accounts for approximately 15% of pediatric and 25% of adult ALL cases. Despite improved outcome over the years, about 25% of children and 50% of adults still fail to respond to intensive chemotherapy protocols or relapse[1]. Improved understanding of T-ALL biology through the identification and characterization of oncogenic lesions is expected to lead to a better prognostic classification and the development of new targeted therapeutic strategies. T-ALL is caused by the accumulation of multiple oncogenic mutations that have been identified through characterization of chromosomal aberrations and Tetrahydrozoline Hydrochloride candidate gene sequencing[2]. Chromosomal translocations in T-ALL frequently involve the T-cell receptor (TCR) loci, wherebyTCRregulatory elements become juxtaposed to genes that are normally not expressed in T-cells[3],[4]. In this way, a specific set of recurrently over-expressed transcription factors (TFs) have been documented, includingTLX1, TLX3, TAL1, LMO1, HOXA, andNKXfamily members[5]. T-ALL samples expressing each of these transcription factors show a distinctive gene expression signature and as such these transcription factors define distinct molecular subtypes in T-ALL[6]. Chromosomal rearrangements Tetrahydrozoline Hydrochloride can Tetrahydrozoline Hydrochloride also lead to large chromosomal deletions and amplifications; to focal gene deletions or amplifications, such asCDKN2Adeletion andMYBduplication[7],[8]; and to in-frame fusion genes encoding chimeric proteins with oncogenic properties such as the constitutively activeNUP214-ABL1fusion kinase[9]. In addition, point mutations and small insertions/deletions (INDELs) have also been described leading to oncogenic events, such as mutations activatingNOTCH1that occur in more than 60% of T-ALL cases[10], or mutations in cytokine receptors and tyrosine kinases such asIL7RandJAK3[11][17]. The latter may lead to new opportunities for molecularly tailored therapies with kinase inhibitors[12],[16],[18],[19]. With the advent of next generation sequencing (NGS) technologies, our sequencing capacity has significantly improved in the past five years. It is now possible to apply targeted re-sequencing, exome sequencing (Exome-seq), whole genome sequencing (WGS), whole transcriptome sequencing (RNA-seq) or a combination of these, to investigate individual genomes, especially those.